Published in J Thromb Haemost on December 23, 2005
Contribution of platelets to tumour metastasis. Nat Rev Cancer (2011) 4.16
Platelet glycoprotein Ib alpha supports experimental lung metastasis. Proc Natl Acad Sci U S A (2007) 1.68
Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood (2010) 1.67
Platelets: linking hemostasis and cancer. Arterioscler Thromb Vasc Biol (2010) 1.29
Structural insights into the interactions between platelet receptors and fibrillar collagen. J Biol Chem (2009) 1.14
Metastasis: recent discoveries and novel perioperative treatment strategies with particular interest in the hemostatic compound desmopressin. Curr Pharm Biotechnol (2011) 0.97
Contributions of thrombin targets to tissue factor-dependent metastasis in hyperthrombotic mice. J Thromb Haemost (2014) 0.88
von-Willebrand factor influences blood brain barrier permeability and brain inflammation in experimental allergic encephalomyelitis. Am J Pathol (2008) 0.87
Periostin Is a Key Niche Component for Wound Metastasis of Melanoma. PLoS One (2015) 0.85
Platelet P2Y12 is involved in murine pulmonary metastasis. PLoS One (2013) 0.84
Gastric cancer-associated enhancement of von Willebrand factor is regulated by vascular endothelial growth factor and related to disease severity. BMC Cancer (2015) 0.81
The novel desmopressin analogue [V4Q5]dDAVP inhibits angiogenesis, tumour growth and metastases in vasopressin type 2 receptor-expressing breast cancer models. Int J Oncol (2015) 0.78
On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis (2013) 0.78
A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients. Springerplus (2015) 0.77
Coagulation and metastasis--an unexpected role for von Willebrand factor. J Thromb Haemost (2006) 0.77
Ganoderma lucidum polysaccharides eradicates the blocking effect of fibrinogen on NK cytotoxicity against melanoma cells. Oncol Lett (2011) 0.76
Expression of stanniocalcin 1 in thyroid side population cells and thyroid cancer cells. Thyroid (2015) 0.76
Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. Clin Exp Metastasis (2016) 0.76
Heparins that block VEGF-A-mediated von Willebrand factor fiber generation are potent inhibitors of hematogenous but not lymphatic metastasis. Oncotarget (2016) 0.75
Functional assessment of von Willebrand factor expression by cancer cells of non-endothelial origin. Oncotarget (2016) 0.75
ADAM23 is downregulated in side population and suppresses lung metastasis of lung carcinoma cells. Cancer Sci (2016) 0.75
Cirrhosis, von Willebrand Factor (vWF) and the Low Incidence of Metastatic Malignancy in Injured Liver. Eurasian J Med (2015) 0.75
Platelet GPIIb supports initial pulmonary retention but inhibits subsequent proliferation of melanoma cells during hematogenic metastasis. PLoS One (2017) 0.75
High relative density of lymphatic vessels predicts poor survival in tongue squamous cell carcinoma. Eur Arch Otorhinolaryngol (2016) 0.75
Use of a rapid assay of subforms of creatine kinase-MB to diagnose or rule out acute myocardial infarction. N Engl J Med (1994) 7.17
Multiple essential functions of neuregulin in development. Nature (1995) 5.66
Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost (2006) 4.58
Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. J Cell Biol (2001) 3.84
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Scatter factor/hepatocyte growth factor and its receptor, the c-met tyrosine kinase, can mediate a signal exchange between mesenchyme and epithelia during mouse development. J Cell Biol (1993) 3.32
Impaired IgG-dependent anaphylaxis and Arthus reaction in Fc gamma RIII (CD16) deficient mice. Immunity (1996) 2.96
Ultrafast bond softening in bismuth: mapping a solid's interatomic potential with X-rays. Science (2007) 2.84
Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest (2000) 2.68
A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost (2006) 2.56
Susceptibility locus for Alzheimer's disease on chromosome 10. Science (2000) 2.49
Plasmodium falciparum domain mediating adhesion to chondroitin sulfate A: a receptor for human placental infection. Proc Natl Acad Sci U S A (1999) 2.41
CYP98A3 from Arabidopsis thaliana is a 3'-hydroxylase of phenolic esters, a missing link in the phenylpropanoid pathway. J Biol Chem (2001) 2.32
Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost (1992) 2.31
Common-sense models of illness: the example of hypertension. Health Psychol (1985) 2.26
Diagnostic marker cooperative study for the diagnosis of myocardial infarction. Circulation (1999) 2.09
Platelets adhere to and translocate on von Willebrand factor presented by endothelium in stimulated veins. Blood (2000) 2.05
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Sequential requirement of hepatocyte growth factor and neuregulin in the morphogenesis and differentiation of the mammary gland. J Cell Biol (1995) 1.91
Scott syndrome, characterized by impaired transmembrane migration of procoagulant phosphatidylserine and hemorrhagic complications, is an inherited disorder. Blood (1996) 1.89
Differentiation between African populations is evidenced by the diversity of alleles and haplotypes of HLA class I loci. Tissue Antigens (2004) 1.86
Evidence that three adhesive proteins interact with a common recognition site on activated platelets. J Biol Chem (1984) 1.83
Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost (2008) 1.81
Congenital upper eyelid eversion complicated by corneal perforation. Br J Ophthalmol (2005) 1.73
Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases. Blood (2001) 1.69
Platelet membrane glycoproteins implicated in ristocetin-induced aggregation. Studies of the proteins on platelets from patients with Bernard-Soulier syndrome and von Willebrand's disease. J Clin Invest (1976) 1.67
Evidence that the Ya and Yc subunits of glutathione transferase B (ligandin) are the products of separate genes. Eur J Biochem (1982) 1.65
Cost-effectiveness of strategies to enhance mammography use. Eff Clin Pract (2001) 1.65
A novel class C beta-lactamase (FOX-2) in Escherichia coli conferring resistance to cephamycins. Antimicrob Agents Chemother (1997) 1.64
Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost (2000) 1.62
Activation of rat liver perisinusoidal lipocytes by transforming growth factors derived from myofibroblastlike cells. A potential mechanism of self perpetuation in liver fibrogenesis. J Clin Invest (1992) 1.62
P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med (2000) 1.61
Circulating procoagulant microparticles in women with unexplained pregnancy loss: a new insight. Thromb Haemost (2001) 1.60
Structure-function relationship of human von Willebrand factor. Blood (1987) 1.60
Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost (2006) 1.59
Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost (1995) 1.58
Thrombotic risk factors in pulmonary hypertension. Eur Respir J (2000) 1.54
Impaired healing of cutaneous wounds and colonic anastomoses in mice lacking thrombin-activatable fibrinolysis inhibitor. J Thromb Haemost (2003) 1.52
Agriculture. Transforming U.S. agriculture. Science (2011) 1.51
International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost (1993) 1.51
Academic stress, power motivation, and decrease in secretion rate of salivary secretory immunoglobulin A. Lancet (1983) 1.49
Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol (1998) 1.49
Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost (2000) 1.48
Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost (2007) 1.42
Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei. J Clin Microbiol (1998) 1.42
A double-blind placebo-controlled study to establish the bifidogenic dose of inulin in healthy humans. Eur J Clin Nutr (2007) 1.38
[Nononcologic abdominal surgery in the elderly]. Chirurg (2005) 1.38
Long-term follow-up of Stargardt's disease and fundus flavimaculatus. Ophthalmology (1998) 1.37
Localized reduction of atherosclerosis in von Willebrand factor-deficient mice. Blood (2001) 1.33
Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost (2007) 1.31
Willebrand factor and ristocetin. I. Mechanism of rustocetin-induced platelet aggregation. Br J Haematol (1974) 1.29
Cloning and developmental expression of the murine neurofilament gene family. Brain Res (1986) 1.28
The zebrafish forkhead transcription factor FoxH1/Fast1 is a modulator of nodal signaling required for organizer formation. Curr Biol (2000) 1.27
Pseudo-von Willebrand's disease. An intrinsic platelet defect with aggregation by unmodified human factor VIII/von Willebrand factor and enhanced adsorption of its high-molecular-weight multimers. N Engl J Med (1982) 1.26
Ser968Thr mutation within the A3 domain of von Willebrand factor (VWF) in two related patients leads to a defective binding of VWF to collagen. Thromb Haemost (2001) 1.25
Effects of cis-diamminedichloroplatinum (NSC-119875) on hearing function in man. Cancer Chemother Rep (1975) 1.24
Haemophilia B due to a de novo insertion of a human-specific Alu subfamily member within the coding region of the factor IX gene. Eur J Hum Genet (1993) 1.24
Multimeric structure of factor VIII/von Willebrand factor in von Willebrand's disease. J Lab Clin Med (1980) 1.19
Alterations in membrane permeability of malaria-infected human erythrocytes are related to the growth stage of the parasite. Biochim Biophys Acta (1982) 1.18
Eccentric localization of von Willebrand factor in an internal structure of platelet alpha-granule resembling that of Weibel-Palade bodies. Blood (1985) 1.18
Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies. Vet Clin Pathol (2005) 1.17
Report from a forum on US heart allocation policy. Am J Transplant (2015) 1.17
von Willebrand factor: the old, the new and the unknown. J Thromb Haemost (2012) 1.16
Behavioral phenotyping of mice lacking the K ATP channel subunit Kir6.2. Physiol Behav (2006) 1.15
Mixed lineage kinase-dependent JNK activation is governed by interactions of scaffold protein JIP with MAPK module components. EMBO J (2001) 1.14
Shear rate dependent inhibition of platelet adhesion and aggregation on collagenous surfaces by antibodies to human factor VIII/von Willebrand factor. Br J Haematol (1980) 1.14
Cysteine-mutations in von Willebrand factor associated with increased clearance. J Thromb Haemost (2005) 1.14
Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost (1999) 1.14
Arterial thrombosis: relevance of a model with two levels of severity assessed by histologic, ultrastructural and functional characterization. J Thromb Haemost (2009) 1.14
Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. J Thromb Haemost (2006) 1.14
Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. J Thromb Haemost (2009) 1.13
Characteristics of Actinobacillus actinomycetemcomitans invasion of and adhesion to cultured epithelial cells. Adv Dent Res (1995) 1.11
Clinical, serologic, and epidemiologic characteristics of ocular toxocariasis. Am J Trop Med Hyg (1979) 1.11
Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome). J Thromb Haemost (2004) 1.10
Standard nomenclature for factor VIII and von Willebrand factor: a recommendation by the International Committee on Thrombosis and Haemostasis. Thromb Haemost (1985) 1.10
Ocular complications of dental local anaesthesia. SADJ (1998) 1.10
Vg1 RBP intracellular distribution and evolutionarily conserved expression at multiple stages during development. Mech Dev (1999) 1.09
Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis (1987) 1.09
The effect of exercise on von Willebrand factor and ADAMTS-13 in individuals with type 1 and type 2B von Willebrand disease. J Thromb Haemost (2007) 1.08
von Willebrand factor ristocetin cofactor activity correlates with platelet function in a high shear stress system. Thromb Haemost (2000) 1.07
Ets transcription factors bind and transactivate the core promoter of the von Willebrand factor gene. Oncogene (1997) 1.07
Purification and partial amino acid sequence of the chloroplast cytochrome b-559. J Biol Chem (1984) 1.07
Heterogeneous abnormalities in the multimeric structure, antigenic properties, and plasma-platelet content of factor VIII/von Willebrand factor in subtypes of classic (type I) and variant (type IIA) von Willebrand's disease. J Lab Clin Med (1983) 1.06
Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost (2000) 1.06
Thrombotic thrombocytopenic purpura and its diagnosis. J Thromb Haemost (2005) 1.05
Orbital fractures in children. Arch Otolaryngol Head Neck Surg (1995) 1.04
Multiple founder haplotypes of mitochondrial DNA in Amerindians revealed by RFLP and sequencing. Ann Hum Genet (1996) 1.04
Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol (1996) 1.03
Ocular anomalies simulating double optic discs. Can J Ophthalmol (1981) 1.03
Activation and substrate specificity of the human protein kinase C alpha and zeta isoenzymes. Eur J Biochem (1993) 1.03
Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood (1996) 1.02
What men say about pregnancy, birth and parenthood. J Psychosom Obstet Gynaecol (1996) 1.02
New variant of von Willebrand disease with defective binding to factor VIII. Blood (1989) 1.02
Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs. Am J Cardiol (1990) 1.02
Diagnosis and treatment of renin-secreting tumors. Report of three cases. Hypertension (1984) 1.01
The function of PTB domain proteins. Kidney Int (1999) 1.01
Willebrand factor and ristocetin. II. Relationship between Willebrand factor, Willebrand antigen and factor VIII activity. Br J Haematol (1974) 1.01
The von Willebrand factor self-association is modulated by a multiple domain interaction. J Thromb Haemost (2005) 1.01
Inhibition of von Willebrand factor-platelet interaction by fibrinogen. Nature (1984) 1.01